Ekaterina Malievskaia net worth and biography

Ekaterina Malievskaia Biography and Net Worth

Major Shareholder of COMPASS Pathways

Ekaterina received her medical degree from St Petersburg Medical Academy in St Petersburg, Russia, and then moved to the US where she completed her Internal Medicine residency training. She worked in private practice, academic medicine and public health for more than 15 years in the greater New York area. She was a Clinical Instructor of Medicine at Mount Sinai School of Medicine, as well as a Research Professor at City University of New York.

After moving to London in 2011, Ekaterina worked in global health and medical philanthropy, focusing on improving outcomes in maternal and child health. She founded Compass Pathways with her husband George Goldsmith in 2016, having experienced at first hand the challenges in accessing evidence-based and effective mental health care for a family member.

What is Ekaterina Malievskaia's net worth?: The estimated net worth of Ekaterina Malievskaia is at least $22.93 million as of March 28th, 2024. Malievskaia owns 4,036,154 shares of COMPASS Pathways stock worth more than $22,925,355 as of December 4th. This net worth approximation does not reflect any other investments that Malievskaia may own. Learn More about Ekaterina Malievskaia's net worth.
How do I contact Ekaterina Malievskaia?: The corporate mailing address for Malievskaia and other COMPASS Pathways executives is , , . COMPASS Pathways can also be reached via phone at 716-676-6461 and via email at [email protected]. Learn More on Ekaterina Malievskaia's contact information.
Has Ekaterina Malievskaia been buying or selling shares of COMPASS Pathways?: Ekaterina Malievskaia has not been actively trading shares of COMPASS Pathways during the last ninety days. Most recently, Ekaterina Malievskaia sold 25,750 shares of the business's stock in a transaction on Thursday, March 28th. The shares were sold at an average price of $8.65, for a transaction totalling $222,737.50. Following the completion of the sale, the insider now directly owns 4,036,154 shares of the company's stock, valued at $34,912,732.10. Learn More on Ekaterina Malievskaia's trading history.
Who are COMPASS Pathways' active insiders?: COMPASS Pathways' insider roster includes George Goldsmith (Major Shareholder), and Ekaterina Malievskaia (Major Shareholder). Learn More on COMPASS Pathways' active insiders.

Ekaterina Malievskaia Insider Trading History at COMPASS Pathways

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
3/28/2024	Sell	25,750	$8.65	$222,737.50	4,036,154
2/26/2024	Sell	17,765	$10.45	$185,644.25	4,092,573
2/23/2024	Sell	11,862	$10.06	$119,331.72	4,110,338
2/6/2024	Sell	19,853	$10.59	$210,243.27	4,144,994
12/13/2023	Sell	2,855	$7.82	$22,326.10	4,264,586
3/29/2022	Sell	6,372	$12.48	$79,522.56

Ekaterina Malievskaia Buying and Selling Activity at COMPASS Pathways

COMPASS Pathways Company Overview

COMPASS Pathways plc operates as a mental health care company in the United Kingdom and the United States. It develops COMP360, a psilocybin therapy that is in Phase III clinical trials for the treatment of treatment-resistant depression; and is in Phase II clinical trials for the treatment of post-traumatic stress disorder and anorexia nervosa. The company was formerly known as COMPASS Rx Limited and changed its name to COMPASS Pathways plc in August 2020. COMPASS Pathways plc was incorporated in 2020 and is headquartered in London, the United Kingdom.

Today's Range

Now: $5.68

$5.06

$5.68

50 Day Range

MA: $5.90

$4.94

$6.84

2 Week Range

Now: $5.68

$2.25

$7.09

Volume

1,674,999 shs

Average Volume

1,458,345 shs

Market Capitalization

$545.39 million

P/E Ratio

N/A

Dividend Yield